疫苗前沿 | 默沙东21价肺炎球菌结合疫苗获突破性疗法认定，包含8种新血清型

参考资料：

[1] Merck Announces U.S. FDA has Granted Breakthrough Therapy Designation for V116, the Company’s Investigational 21-Valent Pneumococcal Conjugate Vaccine, for the Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults. Retrieved April 14, 2022, from https://www.businesswire.com/news/home/20220414005246/en

来源：药明康德

打赏